News Conference News TCT 2024 TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS Todd Neale October 28, 2024
News Conference News TCT 2024 EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis Michael O'Riordan October 28, 2024
News Conference News TCT 2023 Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials Michael O'Riordan October 24, 2023
News Conference News TCT 2023 WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone Todd Neale October 24, 2023
News Conference News EACTS 2023 SWEDEHEART Hints at Mortality Benefit With Statins After SAVR Michael O'Riordan October 05, 2023
News Daily News Patient Risk, Follow-up Duration Drive SAVR, TAVI Outcomes: Meta-analysis Todd Neale January 20, 2023
News Daily News Frailty Before Cardiac Surgery Common, Linked to Adverse Outcomes Michael O'Riordan September 13, 2022
News Daily News Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials Michael O'Riordan March 23, 2022
News Conference News TCT 2021 TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3 Yael L. Maxwell November 05, 2021
News Conference News EuroPCR 2021 Complete 2-Year Data From Evolut Low-Risk Trial ‘Reassuring’ for TAVI Yael L. Maxwell May 19, 2021
News Conference News TCT 2020 Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results Michael O'Riordan October 16, 2020
News Conference News TCT 2020 Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II Todd Neale October 15, 2020
News Daily News Should Guidelines Support TAVR for Low-Risk Patients? Two Views L.A. McKeown August 17, 2020
News Daily News PARTNER 2A at EACTS 2019: ‘The Message Is Exactly the Same’ Shelley Wood October 08, 2019
News Daily News Machine Learning Helps Predict In-Hospital Mortality Post-TAVR, but Skepticism Abounds Todd Neale July 19, 2019
News Conference News ACC 2019 Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery Michael O'Riordan March 17, 2019
News Conference News ACC 2018 NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients Shelley Wood March 10, 2018
News Daily News REPRISE III in Print: Now With Comparison Between Lotus, Evolut R Shelley Wood January 05, 2018